Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.

Wolfe C, Pagano P, Pillar CM, Shinabarger DL, Boulos RA.

Diagn Microbiol Infect Dis. 2018 Nov;92(3):250-252. doi: 10.1016/j.diagmicrobio.2018.06.002. Epub 2018 Jun 19.


Aminomethyl Spectinomycins as Therapeutics for Drug-Resistant Gonorrhea and Chlamydia Coinfections.

Butler MM, Waidyarachchi SL, Connolly KL, Jerse AE, Chai W, Lee RE, Kohlhoff SA, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00325-18. doi: 10.1128/AAC.00325-18. Print 2018 May.


Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.

Ogunniyi AD, Khazandi M, Stevens AJ, Sims SK, Page SW, Garg S, Venter H, Powell A, White K, Petrovski KR, Laven-Law G, Tótoli EG, Salgado HR, Pi H, Coombs GW, Shinabarger DL, Turnidge JD, Paton JC, McCluskey A, Trott DJ.

PLoS One. 2017 Sep 5;12(9):e0183457. doi: 10.1371/journal.pone.0183457. eCollection 2017.


In vitro potency and fungicidal activity of CD101, a novel echinocandin, against recent clinical isolates of Candida spp.

Hall D, Bonifas R, Stapert L, Thwaites M, Shinabarger DL, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Nov;89(3):205-211. doi: 10.1016/j.diagmicrobio.2017.07.007. Epub 2017 Jul 21.


Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines.

Sweeney D, Shinabarger DL, Smart JI, Bruss J, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Sep;89(1):83-85. doi: 10.1016/j.diagmicrobio.2017.05.012. Epub 2017 May 28.


Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Sweeney D, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

Diagn Microbiol Infect Dis. 2017 Feb;87(2):121-128. doi: 10.1016/j.diagmicrobio.2016.11.002. Epub 2016 Nov 12.


Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.

Sweeney D, Stoneburner A, Shinabarger DL, Arhin FF, Belley A, Moeck G, Pillar CM.

J Antimicrob Chemother. 2017 Feb;72(2):622-624. doi: 10.1093/jac/dkw451. Epub 2016 Nov 17. No abstract available.


The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.

Pillar CM, Stoneburner A, Shinabarger DL, Krause KM, Nichols WW.

Lett Appl Microbiol. 2016 Aug;63(2):96-102. doi: 10.1111/lam.12592.


Preclinical development of Ramizol, an antibiotic belonging to a new class, for the treatment of Clostridium difficile colitis.

Rao S, Prestidge CA, Miesel L, Sweeney D, Shinabarger DL, Boulos RA.

J Antibiot (Tokyo). 2016 Dec;69(12):879-884. doi: 10.1038/ja.2016.45. Epub 2016 May 18.


In vitro susceptibility of bovine mastitis pathogens to a combination of penicillin and framycetin: development of interpretive criteria for testing by broth microdilution and disk diffusion.

Pillar CM, Stoneburner A, Shinabarger DL, Abbeloos E, Goby L, Bradley AJ.

J Dairy Sci. 2014 Oct;97(10):6594-607. doi: 10.3168/jds.2014-8027. Epub 2014 Aug 14. Erratum in: J Dairy Sci. 2015 May;98(5):3558. Bradley, Andrew J [added].


Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

Tari LW, Li X, Trzoss M, Bensen DC, Chen Z, Lam T, Zhang J, Lee SJ, Hough G, Phillipson D, Akers-Rodriguez S, Cunningham ML, Kwan BP, Nelson KJ, Castellano A, Locke JB, Brown-Driver V, Murphy TM, Ong VS, Pillar CM, Shinabarger DL, Nix J, Lightstone FC, Wong SE, Nguyen TB, Shaw KJ, Finn J.

PLoS One. 2013 Dec 26;8(12):e84409. doi: 10.1371/journal.pone.0084409. eCollection 2013.


MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.

Butler MM, Shinabarger DL, Citron DM, Kelly CP, Dvoskin S, Wright GE, Feng H, Tzipori S, Bowlin TL.

Antimicrob Agents Chemother. 2012 Sep;56(9):4786-92. doi: 10.1128/AAC.00508-12. Epub 2012 Jun 25.


Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin.

Shinabarger DL, Zurenko GE, Hesje CK, Sanfilippo CM, Morris TW, Haas W.

J Chemother. 2011 Apr;23(2):80-6.


Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.

Butler MM, Williams JD, Peet NP, Moir DT, Panchal RG, Bavari S, Shinabarger DL, Bowlin TL.

Antimicrob Agents Chemother. 2010 Sep;54(9):3974-7. doi: 10.1128/AAC.00484-10. Epub 2010 Jul 12.


Protected nucleotide G2608 in 23S rRNA confers resistance to oxazolidinones in E. coli.

Xu J, Golshani A, Aoki H, Remme J, Chosay J, Shinabarger DL, Ganoza MC.

Biochem Biophys Res Commun. 2005 Mar 11;328(2):471-6.


Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics.

Colca JR, McDonald WG, Waldon DJ, Thomasco LM, Gadwood RC, Lund ET, Cavey GS, Mathews WR, Adams LD, Cecil ET, Pearson JD, Bock JH, Mott JE, Shinabarger DL, Xiong L, Mankin AS.

J Biol Chem. 2003 Jun 13;278(24):21972-9. Epub 2003 Apr 10.


Oxazolidinone antibiotics target the P site on Escherichia coli ribosomes.

Aoki H, Ke L, Poppe SM, Poel TJ, Weaver EA, Gadwood RC, Thomas RC, Shinabarger DL, Ganoza MC.

Antimicrob Agents Chemother. 2002 Apr;46(4):1080-5.


1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes.

Zhou CC, Swaney SM, Shinabarger DL, Stockman BJ.

Antimicrob Agents Chemother. 2002 Mar;46(3):625-9.


Oxazolidinones: a new class of antibacterials.

Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford CW, Tarpley WG.

Curr Opin Pharmacol. 2001 Oct;1(5):470-6. Review.


Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.

Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, Peterson LR, Noskin GA.

Antimicrob Agents Chemother. 2001 Jul;45(7):2154-6.


Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

Xiong L, Kloss P, Douthwaite S, Andersen NM, Swaney S, Shinabarger DL, Mankin AS.

J Bacteriol. 2000 Oct;182(19):5325-31.


The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria.

Swaney SM, Aoki H, Ganoza MC, Shinabarger DL.

Antimicrob Agents Chemother. 1998 Dec;42(12):3251-5.


Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions.

Shinabarger DL, Marotti KR, Murray RW, Lin AH, Melchior EP, Swaney SM, Dunyak DS, Demyan WF, Buysse JM.

Antimicrob Agents Chemother. 1997 Oct;41(10):2132-6.


Interaction of two LysR-type regulatory proteins CatR and ClcR with heterologous promoters: functional and evolutionary implications.

Parsek MR, McFall SM, Shinabarger DL, Chakrabarty AM.

Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12393-7.


Pseudomonas aeruginosa infection in cystic fibrosis: biosynthesis of alginate as a virulence factor.

Roychoudhury S, Zielinski NA, DeVault JD, Kato J, Shinabarger DL, May TB, Maharaj R, Kimbara K, Misra TK, Chakrabarty AM.

Antibiot Chemother (1971). 1991;44:63-7. Review. No abstract available.


Regulation by heme of sterol uptake in Saccharomyces cerevisiae.

Shinabarger DL, Keesler GA, Parks LW.

Steroids. 1989 Mar-May;53(3-5):607-23.


Glyphosate catabolism by Pseudomonas sp. strain PG2982.

Shinabarger DL, Braymer HD.

J Bacteriol. 1986 Nov;168(2):702-7.


Phosphonate Utilization by the Glyphosate-Degrading Pseudomonas sp. Strain PG2982.

Shinabarger DL, Schmitt EK, Braymer HD, Larson AD.

Appl Environ Microbiol. 1984 Nov;48(5):1049-50.

Supplemental Content

Loading ...
Support Center